LAG3 and melanoma: With respect to the future, new combinations with novel agents, such as the anti-lymphocyte activation gene-3 (LAG-3) mAb relatlimab, and potentially also the neo-adjuvant treatment of patients with nodal macro-metastases will be of importance in shaping the field of adjuvant melanoma treatment.